Cargando…
Humoral immunity against SARS-CoV-2 evoked by heterologous vaccination groups using the CoronaVac (Sinovac) and BNT162b2 (Pfizer/BioNTech) vaccines in Chile
INTRODUCTION: Severe acute respiratory syndrome virus 2 (SARS-CoV-2) has caused over million deaths worldwide, with more than 61,000 deaths in Chile. The Chilean government has implemented a vaccination program against SARS-CoV-2, with over 17.7 million people receiving a complete vaccination scheme...
Autores principales: | Díaz-Dinamarca, Diego A., Díaz, Pablo, Barra, Gisselle, Puentes, Rodrigo, Arata, Loredana, Grossolli, Jonnathan, Riveros-Rodriguez, Boris, Ardiles, Luis, Santelises, Julio, Vasquez-Saez, Valeria, Escobar, Daniel F., Soto, Daniel, Canales, Cecilia, Díaz, Janepsy, Lamperti, Liliana, Castillo, Daniela, Urra, Mychel, Zuñiga, Felipe, Ormazabal, Valeska, Nova-Lamperti, Estefanía, Benítez, Rosana, Rivera, Alejandra, Cortes, Claudia P., Valenzuela, María Teresa, García-Escorza, Heriberto E., Vasquez, Abel E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10483147/ https://www.ncbi.nlm.nih.gov/pubmed/37693706 http://dx.doi.org/10.3389/fpubh.2023.1229045 |
Ejemplares similares
-
Validation of a Methodology for the Detection of Severe Acute Respiratory Syndrome Coronavirus 2 in Saliva by Real-Time Reverse Transcriptase-PCR
por: Escobar, Daniel F., et al.
Publicado: (2021) -
The Effects of CoronaVac (Sinovac) and BNT162b2 (BioNTech/Pfizer) Vaccination on Oncologic (18)F-FDG PET/CT Studies
por: Şan, Hüseyin, et al.
Publicado: (2022) -
Cutaneous reactions after CoronaVac and BioNTech vaccines
por: Öner, Ümran, et al.
Publicado: (2022) -
Self-reported reactogenicity of CoronaVac (Sinovac) compared with Comirnaty (Pfizer-BioNTech): A prospective cohort study with intensive monitoring
por: Lai, Francisco Tsz Tsun, et al.
Publicado: (2022) -
Immunogenicity decay and case incidence six months post Sinovac-CoronaVac vaccine in autoimmune rheumatic diseases patients
por: Silva, Clovis A., et al.
Publicado: (2022)